For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit


Learning and Growing with In-House Testing: An Interview with Wei Song, BM, PhD

Keeping molecular testing in-house offers benefits for pathologists, oncologists, and patients

An interview with Wei Song, BM, PhD
Source: The Pathologist
Sponsored by: Thermo Fisher Scientific

Wei Song, BM, PhD
Assistant Professor of Pathology and Laboratory Medicine

How – and why – does your institution conduct precision oncology testing?
Precision medicine is a newly evolving discipline and, to fully realize its potential, all adequately sized institutes should be able to provide in-house genomic profiling for tumors from both tissue and plasma samples. I always think as though I’m running a startup company, so my number one consideration is the customer – who are they and what do they need? Our customers are oncologists and they need genomic profiling tests to enable their patients to benefit from novel precision oncology treatments.

Also, I believe molecular diagnostics is the future of pathology. So while centralization plays an important role currently, if we don’t practice in-house testing, we won’t be able to develop alongside the science and provide the best possible standard of care. That’s why we do as much as possible in-house – to support our clinicians and patients and to keep learning and developing.

Dr. Anna S. Nam Honored with Two Prestigious Awards for Early Career Physician-Scientists

Dr. Anna S. Nam, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine, has received a 2020 Early Independence Award from the National Institutes of Health’s (NIH) High Risk, High Reward Research program and a 2020 Burroughs Wellcome Fund Career Award for Medical Scientists

a woman smiling for a portrait

Dr. Anna S. Nam

The two highly selective awards will provide approximately $2 million in grants to help advance Dr. Nam’s career as she establishes her own laboratory in the Department of Pathology and Laboratory Medicine and mentors other rising scientists at Weill Cornell Medicine.

Dr. Nam received both awards for her innovative work studying blood cell cancers called myeloproliferative neoplasms. Oncologists now routinely identify cancer-causing mutations by sequencing the DNA of patients, which allows them to better predict the course of the disease and select the best therapy. However, for reasons that are currently unknown, there can be differences in outcomes in patients with the same cancer-causing mutations. Dr. Nam’s laboratory is studying how factors beyond genes, like epigenetics or the environment inside a patient’s bone marrow, may play a role.

She has already led the development of a new single-cell RNA sequencing technique that distinguishes blood cells with a cancer-causing mutation from normal blood cells within a patient.

Dr. Alain Borczuk Named Editor in Chief of Archives of Pathology & Laboratory Medicine

Dr. Alain Borczuk

Dr. Alain Borczuk
Professor of Pathology and Laboratory Medicine

After a thorough review of applicants by the Archives Search Committee, CAP President Patrick Godbey, MD, has selected Alain Borczuk, MD, to serve as the next Editor in Chief of the Archives of Pathology & Laboratory Medicine

"I'm thrilled to join the chorus of voices from our department and across the pathology community in congratulating my friend and colleague Dr. Alain Borczuk on his selection as the next Editor-In-Chief of the Archives of Patholoy and Laboratory Medicine. His selection is richly deserved and reflective of his amazing career and contribution to the field of pathology," said Massimo Loda, Chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and Pathologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center.

Please join us in congratulating Dr. Alain Borczuk!

Weill Cornell Medicine Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464 Fax: (212) 746-8192